[go: up one dir, main page]

NO20032597L - Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma - Google Patents

Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma

Info

Publication number
NO20032597L
NO20032597L NO20032597A NO20032597A NO20032597L NO 20032597 L NO20032597 L NO 20032597L NO 20032597 A NO20032597 A NO 20032597A NO 20032597 A NO20032597 A NO 20032597A NO 20032597 L NO20032597 L NO 20032597L
Authority
NO
Norway
Prior art keywords
sarp
scleroderma
prevention
treatment
medicament
Prior art date
Application number
NO20032597A
Other languages
English (en)
Other versions
NO20032597D0 (no
Inventor
Christine Plater-Zyberk
Jacques Colinge
Christine Power
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20032597D0 publication Critical patent/NO20032597D0/no
Publication of NO20032597L publication Critical patent/NO20032597L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
NO20032597A 2000-12-06 2003-06-06 Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma NO20032597L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or prevention of scleroderma

Publications (2)

Publication Number Publication Date
NO20032597D0 NO20032597D0 (no) 2003-06-06
NO20032597L true NO20032597L (no) 2003-06-06

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032597A NO20032597L (no) 2000-12-06 2003-06-06 Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma

Country Status (29)

Country Link
US (2) US7341995B2 (no)
EP (2) EP1411970B1 (no)
JP (1) JP2004525869A (no)
KR (1) KR100804885B1 (no)
CN (1) CN1323716C (no)
AT (1) ATE359808T1 (no)
AU (2) AU2002226366B2 (no)
BG (1) BG107941A (no)
BR (1) BR0115983A (no)
CA (1) CA2428092A1 (no)
CY (1) CY1107687T1 (no)
CZ (1) CZ20031855A3 (no)
DE (1) DE60128009T2 (no)
DK (1) DK1411970T3 (no)
EA (1) EA005973B1 (no)
EE (1) EE200300213A (no)
ES (1) ES2281463T3 (no)
HR (1) HRP20030426A2 (no)
HU (1) HUP0302738A3 (no)
IL (1) IL156069A0 (no)
MX (1) MXPA03005027A (no)
NO (1) NO20032597L (no)
NZ (1) NZ525774A (no)
PL (1) PL365316A1 (no)
PT (1) PT1411970E (no)
SK (1) SK8472003A3 (no)
UA (1) UA83790C2 (no)
WO (1) WO2002046225A2 (no)
YU (1) YU45103A (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE256740T1 (de) * 1997-02-06 2004-01-15 Inst Genetics Llc Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
CA2480084A1 (en) * 2002-04-10 2003-10-16 Applied Research Systems Ars Holding N.V. Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
ES2905923T3 (es) 2005-02-08 2022-04-12 Genzyme Corp Anticuerpos de TGFbeta
EP1948210A4 (en) * 2005-11-08 2010-07-14 Found Biomedical Res & Innov METHOD FOR TREATING ISCHEMIC HEART DISEASE
US20100260785A1 (en) * 2007-12-13 2010-10-14 Gabriela Saborio SARP-1 Fusion Proteins and Uses Thereof
SG192947A1 (en) * 2011-03-11 2013-09-30 Celgene Corp Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
WO2022217037A1 (en) 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4299886B2 (ja) * 1996-09-24 2009-07-22 タノックス インコーポレイテッド アポトーシス関連ペプチドをコードする遺伝子ファミリー、それによってコードされるペプチド、およびそれらの使用方法
US5858715A (en) 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
ATE256740T1 (de) * 1997-02-06 2004-01-15 Inst Genetics Llc Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine

Also Published As

Publication number Publication date
EP1806144A3 (en) 2008-04-23
DE60128009T2 (de) 2007-08-23
PT1411970E (pt) 2007-05-31
AU2002226366B2 (en) 2007-03-22
CN1323716C (zh) 2007-07-04
WO2002046225A2 (en) 2002-06-13
HUP0302738A2 (hu) 2003-11-28
CY1107687T1 (el) 2012-05-23
US20080107627A1 (en) 2008-05-08
EE200300213A (et) 2003-08-15
HRP20030426A2 (en) 2005-04-30
ATE359808T1 (de) 2007-05-15
BG107941A (bg) 2004-01-30
KR20030076585A (ko) 2003-09-26
ES2281463T3 (es) 2007-10-01
NZ525774A (en) 2006-03-31
WO2002046225A3 (en) 2004-01-08
MXPA03005027A (es) 2003-09-05
CN1553806A (zh) 2004-12-08
NO20032597D0 (no) 2003-06-06
EP1411970B1 (en) 2007-04-18
EP1411970A2 (en) 2004-04-28
IL156069A0 (en) 2003-12-23
EP1806144A2 (en) 2007-07-11
US7655628B2 (en) 2010-02-02
UA83790C2 (ru) 2008-08-26
DK1411970T3 (da) 2007-06-04
PL365316A1 (en) 2004-12-27
CA2428092A1 (en) 2002-06-13
YU45103A (sh) 2006-08-17
JP2004525869A (ja) 2004-08-26
HK1068106A1 (zh) 2005-04-22
EA005973B1 (ru) 2005-08-25
DE60128009D1 (de) 2007-05-31
US20050113291A1 (en) 2005-05-26
BR0115983A (pt) 2003-12-30
HUP0302738A3 (en) 2010-01-28
KR100804885B1 (ko) 2008-02-20
SK8472003A3 (en) 2003-10-07
AU2636602A (en) 2002-06-18
EA200300639A1 (ru) 2003-12-25
US7341995B2 (en) 2008-03-11
CZ20031855A3 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
SE0102315D0 (sv) Compounds
ATE246514T1 (de) Paclitaxel enthaltende arzneimittel
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
FI923158A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoidossa
SE9904377D0 (sv) Pharmaceutical combinations
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
DK1352658T3 (da) Forebyggelse eller lægemiddel mod endometriose
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
ATE361757T1 (de) Stabile fumagillin-formulierung
MD980129A (en) Antiherpetic remedy
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
AU2002241162A1 (en) Intimins in the prevention or treatment of infections:ii
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
ITRM20000351A0 (it) Preparato e suo procedimento di preparazione per la prevenzione e/o la cura della caduta di capelli.
IT1304852B1 (it) Miscela di piante medicinali per la prevenzione e la cura delleemorroidi.
ITRM20010494A1 (it) Integratore dietetico per la cura e la prevenzione della miopia.
ITCS20020009A1 (it) Polvere granulosa efficace contro bromidrosi e iperidrosi delle estremita'.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application